Progress in the treatment of bone metastases in cancer patients (Q38002450)

26 August 2017

title

Progress in the treatment of bone metastases in cancer patients (English)

1 reference

26 August 2017

Piotr J Wysocki

3

0 references

author name string

Malgorzata Mackiewicz-Wysocka

series ordinal

1

1 reference

26 August 2017

Magdalena Pankowska

series ordinal

2

1 reference

26 August 2017

language of work or name

English

0 references

publication date

16 April 2012

1 reference

Expert Opinion on Investigational Drugs

26 August 2017

published in

1 reference

26 August 2017

volume

21

1 reference

26 August 2017

issue

6

1 reference

26 August 2017

page(s)

785-795

1 reference

The clinical course of bone metastases from breast cancer

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: focus on the RANK/RANKL axis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

Essential role of macrophage colony-stimulating factor in the osteoclast differentiation supported by stromal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

RANK/RANKL: regulators of immune responses and bone physiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

Mechanisms of bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

Mortality following bone metastasis and skeletal-related events among women with breast cancer: a population-based analysis of U.S. Medicare beneficiaries, 1999-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999-2007).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

Molecular mechanisms of action of bisphosphonates: current status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

Oral clodronate in breast cancer patients with bone metastases: a randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

Ibandronate is effective in preventing skeletal events in patients with bone metastases from colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

Bisphosphonate nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

Bone resorption predicts for skeletal complications in metastatic bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

Growth regulatory properties of endothelins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

Breast-cancer adjuvant therapy with zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

Bone remodelling at a glance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

Efficacy and Safety of Zoledronic Acid in Patients with Breast Cancer Metastatic to Bone: A Multicenter Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679928

10.1517/13543784.2012.679928

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference